Cidara Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of targeted immunotherapies primarily addressing serious diseases in the fields of infectious diseases and oncology. Leveraging its proprietary Cloudbreak® platform, the company creates novel drug-Fc conjugates (DFCs)—single molecule cocktails designed to both inhibit specific disease targets and engage the immune system through a human antibody fragment. This dual-action mechanism aims to improve outcomes for patients with critical unmet medical needs. Cidara’s research and development efforts target complex conditions where conventional therapies may be insufficient, striving to establish new standards of care. Headquartered in San Diego, California, Cidara Therapeutics emphasizes innovation, collaboration, and accountability throughout its organization, seeking to advance immunotherapy solutions that have the potential to transform patient care across key healthcare sectors.